Furiex Pharmaceuticals to present two JNJ-Q2 antibiotic abstracts at ECCMID/ ICC congress

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today announced that two abstracts featuring its antibiotic candidate JNJ-Q2 will be presented at the 2011 joint meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and the International Congress of Chemotherapy (ICC). Furiex is developing JNJ-Q2 for the treatment of acute bacterial skin and skin structure infections and for treatment of community-acquired bacterial pneumonia. The 21st ECCMID/27th ICC congress will be held from May 7 to May 10, 2011 in Milan, Italy.

Titles and copies of JNJ-Q2 abstracts are:

• "Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary (2010) European pathogens isolated from patients with acute bacterial skin and skin structure infections" Abstract P 1138 (D. Farrell, et al.)

• "Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary (2010) European pathogens isolated from patients with community-acquired bacterial pneumonia" Abstract P 1137 (D. Farrell, et al.)